Grant: CIHR Fellowship
McGill University
$135,000.00
Defining mechanisms of action and intervention of Met oncogenic variants in human cancers
FY 2020-21
Summary
Lung cancer is the leading cause of death in men and women in Canada. The high mortality rate is due to the lack of effective therapy for the advanced stage of disease. The Met protein has been associated with development of lung cancer. When Met is overexpressed or activated, it results in abnormal cell growth and tumor formation. Although certain drugs have been developed against Met, patients do not always respond to therapy against Met or develop resistance to the drug. One reason is the lack of understanding of how Met or alterations of Met play a role in tumor development. In this project, I propose to develop a mechanistic understanding of the role of a frequently altered form of Met in lung cancers. Currently, patients with the activated form of Met are selected for clinical trials where drugs against Met are being tested. Using pre-clinical model systems I would like to determine the mechanism of tumor formation caused by altered form of Met protein, as well as test the efficacy of Met inhibitors against tumors expressing the altered form of Met, because patients with this alteration might benefit from Met targeted therapy
Department
Program
CIHR Fellowship
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
440567
Name
Al-Ghabkari Abdulhameed
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Defining mechanisms of action and intervention of Met oncogenic variants in human cancers
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bio Id; Delta Exon 14; Drug Discovery; Juxtamembrane Domain; Mass Spectrometry; Met Rtk; Metastasis; Non Small Cell Lunge Cancer (Nsclc); Patient Derived Xenograft (Pdx); Rna Sequencing
Abstract
Lung cancer is the leading cause of death in men and women in Canada. The high mortality rate is due to the lack of effective therapy for the advanced stage of disease. The Met protein has been associated with development of lung cancer. When Met is overexpressed or activated, it results in abnormal cell growth and tumor formation. Although certain drugs have been developed against Met, patients do not always respond to therapy against Met or develop resistance to the drug. One reason is the lack of understanding of how Met or alterations of Met play a role in tumor development. In this project, I propose to develop a mechanistic understanding of the role of a frequently altered form of Met in lung cancers. Currently, patients with the activated form of Met are selected for clinical trials where drugs against Met are being tested. Using pre-clinical model systems I would like to determine the mechanism of tumor formation caused by altered form of Met protein, as well as test the efficacy of Met inhibitors against tumors expressing the altered form of Met, because patients with this alteration might benefit from Met targeted therapy
Competitiondate
202012
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Al-Ghabkari, Abdulhameed
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~